Bellinzona, August 31, 2020 – MV BioTherapeutics is participating at this important annual event and virtually meet potential investors and licensing partners.
Please contact us for a personal meeting within the partnering system or outside it.
About MV BioTherapeutics
MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications:
1. ApyraVax with the lead indication of Clostridioides difficile infection
2. ApyraMed with lead indications as immune modulator in cancer and beneficial for the gut ecosystem
Research experiments and preclinical trials are performed in the research lab hosted at IRB. The company is looking for seed funding in order to move forward as a fully operational company into clinics with the main indications.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.